# Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

> **NCT07215650** · PHASE1 · RECRUITING · sponsor: **Candid Therapeutics** · enrollment: 44 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** Cizutamig

## Key facts

- **NCT ID:** NCT07215650
- **Lead sponsor:** Candid Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2027-12
- **Final completion:** 2028-04
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215650, "Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07215650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*